TruSight Oncology Comprehensive
Illumina, Inc. · Decision date Sep 4, 2026
What did the FDA decide?
FDA posted a decision dated 2026-09-04 for supplement S008 to PMA P230011, TruSight Oncology Comprehensive from Illumina, Inc. The decision code is OK30, and the supplement type is a 30-Day Notice. The stated reason is a process change involving manufacturer, sterilizer, packager, or supplier, and the statement describes a supplier manufacturing site change.
This notice does not represent a new approval of the whole system or a new indication. The database fields do not state which supplier, which manufacturing site, or what specific manufacturing activity changed. The device is categorized as a next generation sequencing oncology panel, somatic or germline variant detection system under product code PQP and pathology specialty.
FDA approval order statement
a supplier manufacturing site change
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Sep 4, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230011/S008
- Regulatory pathway
- PMA supplement
- Applicant
- Illumina, Inc.
- Product code
- PQP
- Decision code
- OK30
- Decision date
- Sep 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Illumina, Inc.
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230011. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230011 · Original PMA
TruSight Oncology Comprehensive
P230011/S008 received
Application receipt date recorded by FDA.
P230011/S008 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P230011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Illumina, Inc. | PMA approval | Aug 21, 2024 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Illumina, Inc.
- Headquarters
- Not reported
- Brand website
- illumina.com
- FDA applicant address
- 5200 Illumina Way, San Diego, CA, 92122
Sources and methodology
- Original FDA record: P230011/S008
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



